# US 2015/0147401 A1 · Controlled release of biological entities

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147401 A1
- Document ID: US20150147401A1
- Status: Published application
- Kind: A1
- Application number: 14/612,739
- Filed: 2015-02-03
- Published: 2015-05-28
- Earliest claimed: 2004-12-20
- Assignees: Australian Nuclear Science and Technology Organisation
- Applicants: Australian Nuclear Science & Technology Organisation
- Inventors: Kim Suzanne FINNIE; David JACQUES; Christophe Jean Alexandre BARBE; Linggen KONG
- Web page: https://patentgrep.com/patent/US20150147401A1

## CPC

- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/1611: {Inorganic compounds}
- A61K 9/1694: {resulting in granules or microspheres of the matrix type containing more than 5% of excipient}
- A61K 38/1709: {from mammals}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61K 38/4826: {Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)}
- A61K 38/50: acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- B01J 2/08: Gelation of a colloidal solution
- B01J 13/02: Making microcapsules or microballoons {(for medical preparations A61K9/50)}
- A61K 9/501: {Inorganic compounds}
- C12Y 304/21001: Chymotrypsin (3.4.21.1)
- C12Y 304/21062: Subtilisin (3.4.21.62)
- C12Y 305/01005: Urease (3.5.1.5)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C12Y: ENZYMES

## Abstract

A process is provided for releasably encapsulating a biological entity. The process comprises combining a solution of a surfactant in a non-polar solvent with a precursor material and the biological entity to form an emulsion. The emulsion comprises a polar phase dispersed in a non-polar phase, wherein the polar phase comprises the biological entity. The particles comprising the biological entity are then formed from the polar phase.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A particle comprising a releasable biological entity, said particle having an average pore size between about 1 and 50 nm diameter and a mean particle size between about 0.05 and 500 microns.

### Claim 22 (depends on 21)

The particle of claim 21 when made by a process comprising:
a) combining a solution of a surfactant in a non-polar solvent with a precursor material and the biological entity to form an emulsion, said emulsion having a polar phase dispersed in a non-polar phase, and said polar phase comprising the biological entity; and
b) forming particles comprising the biological entity from the polar phase.

### Claim 23 (depends on 21)

The particle of claim 21 comprising an aggregate of primary particles between about 5 and 500 nm in diameter.

### Claim 24 (depends on 21)

The particle of claim 21 wherein the biological entity comprises a protein.

### Claim 25 (depends on 21)

The particle of claim 21 wherein the biological entity is distributed substantially homogeneously through the particle.

### Claim 26 (depends on 21)

The particle of claim 21 wherein the biological entity is biologically active following release from the particle.

### Claim 27 (depends on 21)

A method for delivering a biological entity to a patient comprising administering to the patient one or more particles according to claim 21.

### Claim 28 (depends on 21)

A method for delivering a biological entity to a liquid comprising exposing the liquid to one or more particles according to claim 21.

### Claim 29 (depends on 21)

Use of a particle according to claim 21 for the manufacture of a medicament for the treatment of a condition in a patient, wherein said biological entity is indicated for said treatment.
